JP2019531344A5 - - Google Patents

Download PDF

Info

Publication number
JP2019531344A5
JP2019531344A5 JP2019535993A JP2019535993A JP2019531344A5 JP 2019531344 A5 JP2019531344 A5 JP 2019531344A5 JP 2019535993 A JP2019535993 A JP 2019535993A JP 2019535993 A JP2019535993 A JP 2019535993A JP 2019531344 A5 JP2019531344 A5 JP 2019531344A5
Authority
JP
Japan
Prior art keywords
composition
weight
liquid
crystals
water
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2019535993A
Other languages
English (en)
Japanese (ja)
Other versions
JP2019531344A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/IB2017/001312 external-priority patent/WO2018047013A1/en
Publication of JP2019531344A publication Critical patent/JP2019531344A/ja
Publication of JP2019531344A5 publication Critical patent/JP2019531344A5/ja
Pending legal-status Critical Current

Links

JP2019535993A 2016-09-12 2017-09-12 4−メチル−5−(ピラジン−2−イル)−3h−1,2−ジチオール−3−チオンの処方物、ならびにそれらの製造方法及び使用方法 Pending JP2019531344A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
IN201611031045 2016-09-12
IN201611031045 2016-09-12
US201662412681P 2016-10-25 2016-10-25
US62/412,681 2016-10-25
PCT/IB2017/001312 WO2018047013A1 (en) 2016-09-12 2017-09-12 Formulations of 4-methyl-5-(pyrazin-2-yl)-3h-1, 2-dithiole-3-thione, and methods of making and using same

Publications (2)

Publication Number Publication Date
JP2019531344A JP2019531344A (ja) 2019-10-31
JP2019531344A5 true JP2019531344A5 (enExample) 2020-11-05

Family

ID=60569947

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2019535993A Pending JP2019531344A (ja) 2016-09-12 2017-09-12 4−メチル−5−(ピラジン−2−イル)−3h−1,2−ジチオール−3−チオンの処方物、ならびにそれらの製造方法及び使用方法

Country Status (6)

Country Link
US (1) US11426403B2 (enExample)
EP (1) EP3509642A1 (enExample)
JP (1) JP2019531344A (enExample)
KR (1) KR102658015B1 (enExample)
CN (1) CN109996562A (enExample)
AU (1) AU2017323504A1 (enExample)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7930336B2 (en) 2006-12-05 2011-04-19 Altera Corporation Large multiplier for programmable logic device
AU2017322544B2 (en) * 2016-09-12 2022-06-02 St Ip Holding Ag Formulations of 4-methyl-5-(pyrazin-2-yl)-3H-1.2-dithiole-3-thione, taste-modified formulations, and methods of making and using same

Family Cites Families (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7067116B1 (en) 2000-03-23 2006-06-27 Warner-Lambert Company Llc Fast dissolving orally consumable solid film containing a taste masking agent and pharmaceutically active agent at weight ratio of 1:3 to 3:1
CA2408152A1 (en) 2000-05-05 2001-11-15 Wisconsin Alumni Research Foundation Compositions and methods for protecting cells during cancer chemotherapy and radiotherapy
US7012148B2 (en) 2001-09-25 2006-03-14 Trustees Of Dartmouth College Compositions and methods for thionation during chemical synthesis reactions
US7199122B2 (en) 2001-10-02 2007-04-03 Fox Chase Cancer Center Methods for inhibiting angiogenesis
JP2005522446A (ja) 2002-02-13 2005-07-28 ソルベイ・フアルマ 肺癌の化学予防におけるアネトールジチオールチオンの使用
KR100491318B1 (ko) 2002-11-26 2005-05-24 씨제이 주식회사 올티프라즈(Oltipraz) 제조방법
ATE357932T1 (de) 2003-12-22 2007-04-15 Alcon Inc Mittel zur behandlung von glaukomatöser retinopathie und optischer neuropathie
KR100629771B1 (ko) 2004-01-27 2006-09-28 씨제이 주식회사 결정성이 감소되거나 무정형화된 올티프라즈의 제조방법
PL2486942T3 (pl) * 2004-11-24 2019-05-31 Meda Pharmaceuticals Inc Kompozycje zawierające azelastynę oraz sposoby ich stosowania
FR2879444B1 (fr) 2004-12-22 2007-05-18 Oreal Utilisation d'un compose capable d'augmenter le taux de glutathion dans les melanocytes pour le traitement de la canitie
US20070036733A1 (en) 2005-08-12 2007-02-15 Takasago International Corp. (Usa) Sensation masking composition
CN101257949B (zh) 2005-08-15 2011-01-19 奇华顿股份有限公司 清凉化合物
US7803353B2 (en) 2006-03-29 2010-09-28 The Procter & Gamble Company Oral care compositions having improved consumer aesthetics and taste
GB0704718D0 (en) 2007-03-12 2007-04-18 Prendergast Patrick T Compounds and methods for preventing and treating mucositis
ATE540667T1 (de) 2007-06-13 2012-01-15 Givaudan Sa Verbindungen mit kühlender wirkung
US20110003747A1 (en) 2007-07-20 2011-01-06 Coloumbe Pierre A Use of nrf2 inducers to treat epidermolysis bullosa simplex and related diseases
WO2009099830A2 (en) 2008-01-31 2009-08-13 Mcneil-Ppc, Inc. Edible film-strips for immediate release of active ingredients
US8142806B2 (en) 2008-03-10 2012-03-27 University Of Louisville Research Foundation, Inc. Methods and compositions for controlled delivery of phytochemical agents
US8858995B2 (en) 2008-03-10 2014-10-14 University Of Louisville Research Foundation, Inc. Methods and compositions for controlled delivery of phytochemical agents
KR101057485B1 (ko) 2008-08-04 2011-08-17 서울대학교산학협력단 1,2-디티올티온 유도체를 함유하는 엘엑스알-알파 과다발현으로 인한 질병의 예방 및 치료용 약학 조성물
WO2010128026A2 (en) 2009-05-05 2010-11-11 Givaudan Sa Organic compounds
CN102451469A (zh) * 2010-10-26 2012-05-16 沈阳药科大学 一类用于难溶性药物纳米系统的高效稳定剂
CA2835293C (en) 2011-06-08 2020-08-18 Sti Pharma, Llc Controlled absorption water-soluble pharmaceutically active organic compound formulation for once-daily administration
EP2757887B1 (en) 2011-09-22 2017-04-26 VIIV Healthcare UK Limited Pyrrolopyridinone compounds and methods for treating hiv
US10500282B2 (en) * 2012-12-19 2019-12-10 Kashiv Biosciences, Llc Supersaturated stabilized nanoparticles for poorly soluble drugs
WO2015023889A1 (en) 2013-08-16 2015-02-19 Luminus Biosciences Inc. Rapidly-dissolving thin film formulation of water soluble digitalis glycoside for the treatment of congestive heart disease
EP3110510A1 (en) 2014-02-27 2017-01-04 The Procter & Gamble Company Oral care compositions with a reduced bitter taste perception
US20160376259A1 (en) * 2015-06-25 2016-12-29 St Ip Holding Ag Methods for Preparing Oltipraz
WO2016207914A2 (en) 2015-06-25 2016-12-29 St Ip Holding Ag Methods for preparing oltipraz
ITUB20159655A1 (it) 2015-12-23 2017-06-23 Bormioli Rocco Spa Capsula di sicurezza di un contenitore.
ITUA20162141A1 (it) 2016-03-31 2017-10-01 Bormioli Pharma Spa Capsula di chiusura
AU2017322544B2 (en) * 2016-09-12 2022-06-02 St Ip Holding Ag Formulations of 4-methyl-5-(pyrazin-2-yl)-3H-1.2-dithiole-3-thione, taste-modified formulations, and methods of making and using same
KR20180123796A (ko) 2017-05-10 2018-11-20 서울대학교산학협력단 Nrf2-NEMO 경로 활성화를 통한 과중력으로 인한 세포괴사의 억제용 조성물 및 방법

Similar Documents

Publication Publication Date Title
ES2903383T3 (es) Preparación de complejos sólidos de ciclodextrina para la administración de un principio farmacéutico activo oftálmico
US20200246278A1 (en) Injectable diethylstilbestrol nanosuspension formulation
JP5587198B2 (ja) タキサン誘導体を含有する、安定性が改良された凍結乾燥医薬組成物、及びその製法
CN102421451B (zh) 苯达莫司汀环多糖组合物
Kolawole et al. Formulation and evaluation of paclitaxel-loaded boronated chitosan/alginate nanoparticles as a mucoadhesive system for localized cervical cancer drug delivery
US12397001B2 (en) Treatment of ocular inflammation with ophthalmic compositions
JP2013545752A5 (enExample)
JP2010510241A5 (enExample)
CN104136012A (zh) 制备装载有活性物质的纳米颗粒的方法
JP6571166B2 (ja) アリピプラゾールプロドラッグ組成物
Praphanwittaya et al. Aqueous solubility of kinase inhibitors: I the effect of hydrophilic polymers on their γ-cyclodextrin solubilization
CN108697683A (zh) 口服紫杉烷组合物和方法
CN108883064B (zh) 包含pvp-i的眼用组合物
KR20210044245A (ko) 주사가능 약학 조성물 및 이의 제조 방법
JP2020073564A5 (enExample)
EP4284334A1 (en) Pharmaceutical composition comprising a diphenylpyrazine derivative
WO2007042572A1 (en) Chitosan and heparin nanoparticles
CN114007588A (zh) 比拉斯汀的稳定和保存的药物组合物
Öztürk et al. Mixed micelles formulation for carvedilol delivery: In-vitro characterization and in-vivo evaluation
WO2022061120A1 (en) Solid dispersions containing amorphous nintedanib, their synthesis and use thereof
US20240058358A1 (en) Ph stabilized topical ophthlamic compositions
JP2018508487A (ja) デュタステリド含有固体分散体及びこれを含む組成物
JP2019533008A5 (enExample)
TW201922250A (zh) 比拉斯汀(bilastine)的水性組成物
US20170231981A1 (en) Compositions of multiple aripiprazole prodrugs